Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

Back to Item »

Phase III Study Shows Exelixis’ Cabozantinib Nearly Triples PFS in Metastatic Medullary Thyroid Cancer

Firm has recently completed NDA submission to FDA for MTC and continues development against other cancers.

Forward this item to a colleague:


 
   

(Separate multiple addresses by commas)

   

(Separate multiple addresses by commas)

Be sure to take the GEN Poll

CRISPR Patent Controversy

Do you think recently released email from a former Broad Institute scientist to Jennifer Doudna will expedite a final legal decision on who owns the CRISPR patent?

More »